Rudy B.
- Country
- France
- Department
- Hôpital Cochin - Service d'hématologie clinique
Research Overview
- Phase 1 Study of Actinomycin D Combined with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
- Phase I/II Open-Label Study of Azacitidine and Venetoclax in Untreated Higher-Risk Myelodysplastic Syndromes Ineligible for Allogeneic Transplantation
- Phase II Evaluation of Azacitidine and Venetoclax Combination Therapy in Higher-Risk Chronic Myelomonocytic Leukemia Patients
Data & Insights
Has run more than one trial at 18 of 27 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating advanced blood disorders, with particular emphasis on myelodysplastic syndromes and chronic myelomonocytic leukemia.
- Higher-risk MDS treatment
- CMML therapeutic approaches
- Novel combination therapies
Research activities focus on innovative therapeutic combinations including ONUREG and Venetoclax for patients ineligible for transplantation.
Therapeutic Innovation
Expertise centers on developing treatment strategies for patients with higher-risk hematologic conditions, particularly exploring drug combinations with Azacitidine.
- Combined therapy approaches
- Alternative treatment options
- Non-transplant therapies
The investigator evaluates treatment safety and efficacy in patients who cannot undergo traditional transplantation procedures.
Clinical Assessment
Specialized focus on determining optimal therapeutic protocols for high-risk blood disorders, including dosing strategies and treatment duration optimization.
- Treatment response evaluation
- Safety profile assessment
- Risk-stratified approaches
Research encompasses evaluation of treatment responses in specific patient populations with advanced hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.